Investigación

Leucemia y hemopatías pediátricas

Buscador de publicaciones

Publicaciones

  • Bardón-Cancho EJ, Marco-Sánchez JM, Benéitez-Pastor D, Payán-Pernía S, Llobet AR, Berrueco R, García-Morin M, Beléndez C, Senent L, Acosta MJO, Pleguezuelos IP, Velasco P, Collado A, Moreno-Servet M, Argilés B, de Soto IP, Del Mar Bermúdez M, Salido Fiérrez EJ, Blanco-Álvarez A, Navarro PG and Cela E.

    Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with ß-thalassemia

    ANNALS OF HEMATOLOGY . 103(5): 1525-1539. Nº de citas: 1

    [doi:10.1007/s00277-024-05694-z]

  • Juan-Ribelles A, Bautista F, Cañete A, Rubio-San-Simón A, Alonso-Saladrigues A, Hladun R, Rives-Solà S, Dapena JL, Fernández JM, Lassaletta Á, Cruz-Martínez O, Ramírez-Villar G, Fuster JL, de Heredia CD, García-Ariza M, Quiroga E, Del Mar Andrés M, Verdú-Amorós J, Molinés A, Herrero B, López M, Márquez C, Toboso M, Lendínez F, Sirvent JG, Tallón M, Rodríguez G, Acha T, Moreno L and Fernández-Teijeiro A.

    ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(9): 2351-2359.

    [doi:10.1007/s12094-024-03445-0]

  • Jiménez-Yuste, V, Alvarez-Román, MA, Berrueco R, Bonanad, S, Calvo-Villas, JM, González-González, R, Porras, JRG, Núñez-Vázquez, RJ and Rodríguez-López, M.

    Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab

    TH OPEN . 08(02): 194-201.

    [doi:10.1055/s-0044-1785525]

  • Llurba E, Fàtima Crispi Brillas, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.

    Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.

    BMJ Open . 14(3): . Nº de citas: 1

    [doi:10.1136/bmjopen-2023-076201]

  • Velasco-Hernandez, T, Trincado, JL, Vinyoles, M, Closa, A, Martínez-Moreno, A, Gutiérrez-Agüera, F, Molina, O, Rodríguez-Cortez, VC, Ximeno-Parpal, P, Fernández-Fuentes, N, Petazzi, P, Beneyto-Calabuig, S, Velten, L, Romecin, P, Casquero, R, Abollo-Jiménez, F, de la Guardia, RD, Lorden, P, Bataller, A, Lapillonne, H, Stam, RW, Vives, S, Torrebadell-Burriel M, Fuster, JL, Bueno, C, Sarry, JE, Eyras, E, Heyn, H and Menéndez, P.

    Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

    hemasphere . 8(2): . Nº de citas: 3

    [doi:10.1002/hem3.45]

  • Gutierrez-Camino A, Caron M, Richer C, Fuchs C, Illarregi U, Poncelet L, St-Onge P, Bataille AR, Tremblay-Dauphinais P, Lopez-Lopez E, Camós-Guijosa M, Ramirez-Orellana M, Astigarraga I, Lécuyer É, Bourque G, Martin-Guerrero I and Sinnett D.

    CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(3): .

    [doi:10.3390/ijms25031477]

  • Ramamoorthy S, Lebrecht D, Schanze D, Schanze I, Wieland I, Andrieux G, Metzger P, Hess M, Albert MH, Borkhardt A, Bresters D, Buechner J, Català-Temprano A, De Haas V, Dworzak M, Erlacher M, Hasle H, Jahnukainen K, Locatelli F, Masetti R, Stary J, Turkiewicz D, Vinci L, Wlodarski MW, Yoshimi A, Boerries M, Niemeyer CM, Zenker M and Flotho C.

    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup

    BRITISH JOURNAL OF HAEMATOLOGY . 204(2): 595-605. Nº de citas: 1

    [doi:10.1111/bjh.19190]

  • Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, Bufalo FD, Rives-Solà S, Jacoby E, Balduzzi A, Bourquin JP and Baruchel A.

    Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.

    JOURNAL OF CLINICAL ONCOLOGY . 42(3): 253-257. Nº de citas: 4

    [doi:10.1200/JCO.23.01314]

  • Molina O, Ortega-Sabater C, Thampi N, Fernández-Fuentes N, Guerrero-Murillo M, Martínez-Moreno A, Vinyoles M, Velasco-Hernández T, Bueno C, Trincado JL, Granada I, Campos D, Giménez C, Boer JM, den Boer ML, Calvo GF, Camós-Guijosa M, Fuster JL, Velasco P, Ballerini P, Locatelli F, Mullighan CG, Spierings DCJ, Foijer F, Pérez-García VM and Menéndez P.

    Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

    EMBO Molecular Medicine . 16(1): 64-92. Nº de citas: 2

    [doi:10.1038/s44321-023-00006-w]

  • Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell-Burriel M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives-Solà S and Pérez-Simón JA.

    Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

    FRONTIERS IN IMMUNOLOGY . 14: 1280580-1280580. Nº de citas: 5

    [doi:10.3389/fimmu.2023.1280580]